TCL Archive ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial. September 8, 2006
TCL Archive FDA Says Bristol’s UFT “Not Approvable” For Colorectal Cancer, Contrary To ODAC. March 30, 2001
